Thomas Powles, MD, on Urothelial Carcinoma: Results From the IMvigor211 Trial

2018 Genitourinary Cancers Symposium
Tweet this page

Thomas Powles, MD, of Barts Cancer Institute, discusses phase III study findings on atezolizumab vs chemotherapy in platinum-treated locally advanced or metastatic urothelial carcinoma, with an emphasis on immune biomarkers, tumor mutational burden, and clinical outcomes (Abstract 409).

Advertisement

Advertisement

Advertisement